Shionogi Expands ALS Research with Real-World Data Partnership
Event summary
- Shionogi partners with the ALS/MND Natural History Consortium to collect real-world data on ALS, reinforcing its commitment to ALS research.
- The collaboration focuses on accessing NeuroBANK®, a patient-centered observational platform with over 4,500 ALS patients enrolled across 18 clinics in the U.S., Europe, and Israel.
- Shionogi aims to deepen scientific knowledge of ALS through real-world data, including data on approved therapies like RADICAVA ORS® (edaravone).
- The partnership underscores Shionogi's strategic investment in rare disease research, following its acquisition of the global RADICAVA business.
The big picture
Shionogi's partnership with the ALS/MND Natural History Consortium underscores its strategic focus on rare disease research, particularly in ALS. The collaboration aligns with broader industry trends toward leveraging real-world data to enhance clinical trial design and therapeutic development. With over 4,500 patients enrolled in NeuroBANK®, Shionogi gains access to a robust dataset that could inform future drug development efforts and reinforce its position as a key player in the ALS space.
What we're watching
- Data Utilization
- How Shionogi leverages real-world data to accelerate ALS drug development and improve patient outcomes.
- Regulatory Strategy
- Whether the insights gained from this partnership will support future regulatory filings for new ALS treatments.
- Competitive Positioning
- The pace at which Shionogi can differentiate itself in the ALS therapeutic landscape through targeted research investments.
Related topics